Zhejiang Medicine Co Ltd (600216):企業の財務・戦略的SWOT分析

◆英語タイトル:Zhejiang Medicine Co Ltd (600216) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C12936
◆発行会社(調査会社):GlobalData
◆発行日:2019年1月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Zhejiang Medicine Co Ltd (600216) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Zhejiang Medicine Co Ltd (Zhejiang Medicine) develops, manufactures and markets biological drugs, pharmaceutical intermediates and bio-pesticides. The company’s product portfolio consists of animal nutrition, active pharmaceutical ingredients (APls) and intermediates; antibiotics and human nutrition products including vitamin E, natural vitamin E, vitamin A, vitamin H, vitamin D3, coenzyme Q10, beta-carotene, fat-soluble vitamins, carotenoids and other pharmaceutical preparations. The company provides its products in large and small volume injections, freeze dried powder injections, tablets, hard and soft capsules, pills and oral solutions. It has two research and development (R&D) centers, namely, Shaoxing Research Institute of Pharmaceutical Industry and Shanghai Health Creation Biological Drug Research and Development Center. Zhejiang Medicine is headquartered in Shaoxing, Zhejiang, China.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Zhejiang Medicine Co Ltd – Key Facts 5
Zhejiang Medicine Co Ltd – Key Employees 6
Zhejiang Medicine Co Ltd – Key Employee Biographies 7
Zhejiang Medicine Co Ltd – Key Operational Employees 8
Zhejiang Medicine Co Ltd – Major Products and Services 9
Zhejiang Medicine Co Ltd – History 11
Zhejiang Medicine Co Ltd – Company Statement 13
Zhejiang Medicine Co Ltd – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 15
Company Overview 15
Zhejiang Medicine Co Ltd – Business Description 16
R&D Overview 16
Zhejiang Medicine Co Ltd – Corporate Strategy 17
Zhejiang Medicine Co Ltd – SWOT Analysis 18
SWOT Analysis – Overview 18
Zhejiang Medicine Co Ltd – Strengths 18
Zhejiang Medicine Co Ltd – Weaknesses 19
Zhejiang Medicine Co Ltd – Opportunities 20
Zhejiang Medicine Co Ltd – Threats 21
Zhejiang Medicine Co Ltd – Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios – Capital Market Ratios 23
Financial Ratios – Annual Ratios 24
Financial Performance 26
Financial Ratios – Ratio Charts 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances 28
Zhejiang Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 28
Zhejiang Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019 29
Zhejiang Medicine Co Ltd, Recent Deals Summary 30
Section 5 – Appendix 31
Methodology 31
Ratio Definitions 31
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Zhejiang Medicine Co Ltd, Key Facts 5
Zhejiang Medicine Co Ltd, Key Employees 6
Zhejiang Medicine Co Ltd, Key Employee Biographies 7
Zhejiang Medicine Co Ltd, Key Operational Employees 8
Zhejiang Medicine Co Ltd, Major Products and Services 9
Zhejiang Medicine Co Ltd, History 11
Zhejiang Medicine Co Ltd, Subsidiaries 14
Zhejiang Medicine Co Ltd, Key Competitors 22
Zhejiang Medicine Co Ltd, Ratios based on current share price 23
Zhejiang Medicine Co Ltd, Annual Ratios 24
Zhejiang Medicine Co Ltd, Annual Ratios (Cont...1) 25
Zhejiang Medicine Co Ltd, Annual Ratios (Cont...2) 26
Zhejiang Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 28
Zhejiang Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019 29
Zhejiang Medicine Co Ltd, Recent Deals Summary 30
Capital Market Ratios 31
Equity Ratios 32
Profitability Ratios 32
Cost Ratios 33
Liquidity Ratios 33
Leverage Ratios 33
Efficiency Ratios 34

List of Figures
Zhejiang Medicine Co Ltd, Ratio Charts 27
Zhejiang Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 28
Zhejiang Medicine Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019 29

★海外企業調査レポート[Zhejiang Medicine Co Ltd (600216):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Visterra Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Visterra Inc (Visterra), formerly Parasol Therapeutics Inc is a clinical-stage biopharmaceutical company that develops antibody therapies for the treatment of infectious diseases. The company develops precision antibody-based biological medicines for infectious and non-infectious diseases. I …
  • Toppan Printing Co., Ltd.:戦略・SWOT・企業財務分析
    Toppan Printing Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toppan Printing Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Myriad Genetics, Inc.:企業の戦略・SWOT・財務分析
    Myriad Genetics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Myriad Genetics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Salix Pharmaceuticals Ltd:企業のM&A・提携動向(医療分野)
    Summary Salix Pharmaceuticals Ltd (Salix) is a specialty pharmaceutical company. It develops and markets prescription pharmaceutical products for the prevention, treatment and diagnosis of gastrointestinal (GI) diseases. The company also in-licenses and acquires late-stage and marketed proprietary t …
  • Dawnrays Pharmaceutical (Holdings) Ltd (2348):企業財務及び戦略的SWOT分析
    Summary Dawnrays Pharmaceutical (Holdings) Ltd (Dawnrays) is a drug manufacturing company that develops, manufactures and markets cephalosporin antibiotics and specific medicines. The company’s products include cefoperazone sodium and sulbactam sodium sterile, cefoperazone sodium sterile, ceftazidim …
  • Toa Corporation:企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Toa Corporation" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly follows a …
  • FormFactor, Inc. (FORM):企業財務及び戦略的SWOT分析
    Summary FormFactor, Inc. (FormFactor) is an electronic equipment company that offers manufacturing and distribution of semiconductors. The company offers probe cards to manufacturers of dram, flash and socs. Its DRAM wafer probe card has three-dimensional MEMs probe spring design that supports fan-i …
  • China Daye Non-Ferrous Metals Mining Limited:企業の戦略・SWOT・財務情報
    China Daye Non-Ferrous Metals Mining Limited - Strategy, SWOT and Corporate Finance Report Summary China Daye Non-Ferrous Metals Mining Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • ActogeniX NV:製品開発パイプライン動向2015
    ActogeniX NV - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘ActogeniX NV - Product Pipeline Review - 2015’, provides an overview of the ActogeniX NV’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developm …
  • Bend Research Inc-製薬・医療分野:企業M&A・提携分析
    Summary Bend Research Inc (Bend Research), a subsidiary of Capsugel Inc is a provider of drug delivery technologies and formulation development services. The company offers services such as formulation science, dosage form development, process development, engineering, cGMP manufacturing, bioprocess …
  • DFC Global Corp. (formerly Dollar Financial Corp.):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' DFC Global Corp. (formerly Doll …
  • Global Ports Holding PLC (GPH):企業の財務・戦略的SWOT分析
    Global Ports Holding PLC (GPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Curtiss-Wright Corporation (CW):企業のM&A・提携動向(エネルギー分野)
    Summary Curtiss-Wright Corporation (Curtiss-Wright) designs and manufactures highly engineered, technologically advanced products and services. The company provides products and services in the areas of motion control, flow control and electro mechanical treatment. The company’s products portfolio i …
  • Aksigorta A.S. (AKGRT):企業の財務・戦略的SWOT分析
    Aksigorta A.S. (AKGRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Graphite India Limited (GRAPHITE):企業概要、財務及び戦略的SWOT分析
    Summary Graphite India Limited (GIL) is a graphite electrode producer. The company offers products such as graphite electrodes, speciality products, carbon products, impervious graphite equipment, glass reinforced plastic pipes, and others. It also generates power through hydro and multi fuel routes …
  • Telstra Corporation Limited:企業のM&A・提携・投資分析
    Telstra Corporation Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Telstra Corporation Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • PledPharma AB (PLED):企業概要、財務及び戦略的SWOT分析
    Summary PledPharma AB (PledPharma) is a pharmaceutical company. The company develops pharmaceutical products for oncology market. Its products under clinical development include PP-095, and PP-099. PledPharma’s products are used in the therapeutic areas of cardiology and oncology. The company evalua …
  • Exmar NV/SA (EXM):企業財務及び戦略的SWOT分析
    Summary Exmar NV/SA (Exmar), a subsidiary of Compagnie Maritime Belge SA is an energy supply chain provider that offers turnkey solution for the LNG industry. The company offers services such as floating liquefaction, floating regasification, LNG shipping, ship-to-ship transfers, floating production …
  • UCB SA (UCB):医療機器:M&Aディール及び事業提携情報
    Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines …
  • Fujimi Incorporated (5384):企業財務及び戦略的SWOT分析
    Summary Fujimi Incorporated (Fujimi) is a chemical company that manufactures and markets synthetic precision abrasives. The company’s products include silicon wafers, semiconductor devices, hard disks, specialty materials and thermal spray materials. It offers wire-saw slicing abrasives for solar po …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆